Cancer is the second leading cause of death in the United States, accounting for approximately 25% of deaths. The national medical expenditures of cancer reached $125 billion in 2010, and are projected to increase to $158 billion by 2020. A recent Institute of Medicine report, entitled ?Delivering high-quality cancer care: Charting a new course for a system in crisis,? expressed major concerns over the unsustainable increase in the cost of cancer care, identifying rapid diffusion of new technologies and the aging demographic as key cost drivers. The objective of the proposed study is to examine the impact of technology diffusion in medical, radiation, and surgical oncology on the costs and outcomes of cancer care.
Specific aims of the study are: (1) to describe the pattern of technology diffusion in medical, radiation, and surgical oncology in the top five most expensive cancers and assess the geographic variation of the diffusion pattern; (2) to examine factors associated with the diffusion of new technologies and those that contribute to the geographic variations in new technology diffusion; (3) to evaluate the impact of the diffusion of new oncologic technologies on health outcomes and whether the impact would be modified by guideline adherence; and (4) to estimate the effect of the diffusion of new oncologic technologies on the cost of cancer care and geographic variation in healthcare spending, and to explore for each cancer whether these new technologies are substitute or complementary to existing treatment. We will address our research questions using a cohort of cancer patients extracted from the SEER-Medicare and MarketScan? databases, focusing on the top five most expensive cancers: female breast, colorectal, lymphoma, lung, and prostate cancer. Our study will provide a comprehensive evaluation of the current state of technology diffusion for all modalities involved in the treatment of cancer, paying special attention to market and organizational characteristics tied to providers? financial incentives. The choice of cancer to study technology diffusion offers a unique opportunity to understand the complicated interactions between new and existing technologies and allows us to explore the substitution or complementary effect of new technologies, both within the same class of technology and across classes. Findings from our study will assist policy makers in the design and planning dissemination and implementation strategies to maximize the benefit of effective new treatments while taking into consideration of the cost implications to the cancer care delivery system.
STATEMENT Cancer is the second leading cause of death in the United States and may soon surpass heart disease to become the leading cause of death; national medical expenditure of cancer is projected to reach $158 billion by 2020 and rapid diffusion of new technologies is believed to be one of the key drivers of escalating cancer care costs. We will analyze real-world, population-based data to examine the diffusion pattern of new technology in medical, radiation, and surgery oncology and its impact on the costs and health outcomes of cancer patients. Findings from this research will help policy makers design optimal strategies to disseminate effective new treatments to cancer patients.
|Kim, Charissa R; Kim, Bumyang; Ning, Matthew S et al. (2018) Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer 19:e517-e528|
|Guo, Fangjian; Kuo, Yong-Fang; Shih, Ya Chen Tina et al. (2018) Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer 124:3500-3509|
|Pan, Hubert Y; Jiang, Jing; Hoffman, Karen E et al. (2018) Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol 36:1823-1830|
|Shih, Ya-Chen Tina; Nasso, Shelley Fuld; Zafar, S Yousuf (2018) Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care. Pharmacoeconomics 36:259-261|
|Chien, Chun-Ru; Geynisman, Daniel M; Kim, Bumyang et al. (2018) Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. Pharmacoeconomics :|
|Shen, Chan; Zhao, Bo; Liu, Lei et al. (2018) Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Cancer 124:364-373|
|Shaitelman, Simona F; Lei, Xiudong; Thompson, Alastair et al. (2018) Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol :JCO1800317|
|Swanick, Cameron W; Lei, Xiudong; Xu, Ying et al. (2018) Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors: A Population-Based Survey Study. Int J Radiat Oncol Biol Phys 100:882-890|
|Shih, Ya-Chen Tina; Shen, Chan; Hu, Jim C (2017) Do Robotic Surgical Systems Improve Profit Margins? A Cross-Sectional Analysis of California Hospitals. Value Health 20:1221-1225|
|Smith, Benjamin D (2017) Chemotherapy First, Then Select for Local Therapy. Int J Radiat Oncol Biol Phys 97:449|
Showing the most recent 10 out of 16 publications